Oncology | pharmaphorum

Saturday 25 July 2026

Oncology

News

Roche's oral SERD comes good in 2nd-line breast cancer trial

Roche's oral SERD comes good in 2nd-line breast cancer trial

Roche has staked a claim to use its oral SERD giredestrant as a second-line therapy for breast cancer, regardless of a patient's ESR1 mutation status.

News

Keytruda box and bottle

FDA clears subcutaneous Keytruda in a boost to MSD

MSD's Keytruda will soon be available as a subcutaneous injection, improving convenience for patients and defending it from a looming patent loss.

Oncology

Prostate Cancer Awareness blue ribbon on blue background

Current and future standard of care in prostate cancer

Despite recent advancements in the field of prostate cancer treatment, there remain distinct gaps in the current standard of care needing improvement.

News

Imfinzi becomes first NHS drug for aggressive lung cancer

Imfinzi becomes first NHS drug for aggressive lung cancer

AstraZeneca's PD-L1 inhibitor Imfinzi is the first drug therapy to be recommended for routine NHS use in limited-stage small cell lung cancer.

Oncology

12 Question with Rick Coope

Sponsored

12 Questions with Rick Coope

Rick Coope is General Manager at Menarini Stemline UK, Ireland, and the Nordics.

Digital

health technology

AI medicines are coming: Building the foundations for discov...